Lilly's gastric cancer drug meets late-stage goal

Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.

The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.

The study, named REGARD, also improved survival without the cancer worsening.